Patients with migraine are more likely to fill a new prescription and adhere to a new therapy when their preferred dosing regimen is available, a new study found. Researchers evaluated the impact of having flexible dosing options on acceptance of and adherence to a new migraine preventive therapy class among adults with migraine. In this observational study, 2 online surveys were completed: one by physicians currently treating adult patients with migraine and the other by adults with migraine. Both surveys presented the participants with 2 scenarios: only monthly, only quarterly. Both dosing options of the new medication are available. Among the findings:

• 400 physicians and 417 US adults with migraine completed the surveys.
• The availability of both dosing options yielded a significant increase in the proportion of patients expected to receive the new medication.
• The overall proportion of patients favoring monthly dosing (35%) was similar to the proportion favoring quarterly dosing (40%).